Press Releases
 
Press Releases
  Date Title and Summary View
Dec 19, 2014
MADISON, Wis.--(BUSINESS WIRE)-- The Centers for Medicare and Medicaid Services (CMS) has informed representatives of Exact Sciences that next week the agency will be issuing a correction to the 2015 lab fee schedule. Consistent with the November 25th final payment decision, CMS will reimburse Cologuard based ...
Dec 19, 2014
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) — The reimbursement amount published today for Cologuard in the 2015 Clinical Diagnostic Laboratory Fee Schedule is inconsistent with what the Centers for Medicare and Medicaid Services (CMS) publicly communicated on November 25, ...
Dec 16, 2014
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corporation (NASDAQ: EXAS) today announced the pricing of the public offering of 4,000,000 common shares previously sold to Jefferies LLC and Robert W. Baird & Co. Incorporated, as underwriters of the offering. The common shares will be sold at a public offering pri...
Dec 15, 2014
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corporation (NASDAQ: EXAS) today announced an agreement to sell 4,000,000 shares of its common stock to Jefferies LLC and Robert W. Baird & Co. Incorporated as underwriters in an underwritten public offering pursuant to its effective shelf registration statement ...
Dec 2, 2014
First and only FDA-approved noninvasive stool DNA screening test for colorectal cancer MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced that Mercy Hospital St. Louis will now offer Cologuard®, the first and only FDA-approved noninvas...
Nov 25, 2014
CMS payment level supports patient access to the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced that the Centers for Medicare & Medicaid Services (CMS) has is...
Nov 12, 2014
Exact Sciences' new colon cancer screening test recognized as a revolution in healthcare MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced Cologuard has received a 2014 "Best of What's New" award from Popular Science. Colog...
Nov 6, 2014
Updated guidelines include recommended use of noninvasive stool-based DNA screening test every three years MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced that the American Cancer Society's Colorectal Cancer Prevention and Early Detection ...
Nov 5, 2014
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in three investor conferences during November. Maneesh K. Arora, the company's chief operating officer, will participate in a fireside chat at the Stephens Fall Investment ...
Oct 29, 2014
Meriter partners with Exact Sciences in effort to get more patients screened for colorectal cancer MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced that Meriter-UnityPoint Health will now offer Cologuard®, the first and only FDA appr...
Page:
1
... NextLast
= add release to Briefcase